News & Views

  • CRO Provides Drug Discovery Assays to Medicines Catapult
 

CRO Provides Drug Discovery Assays to Medicines Catapult  

Mar 30 2019 Read 359 Times

A UK-based human tissue research company has announced a strategic partnership with Medicines Discovery Catapult. REPROCELL Europe Ltd, which has joined the Catapult’s Virtual R&D platform, aims to overcome the logistical and ethical challenges surrounding the use of human tissue in pre-clinical drug development by providing contract laboratory services in predictive human fresh tissue assays. As a GLP-accredited CRO, it can use these human ex-vivo pharmacology models as a way to bridge the gap between in-vivo data and clinical trials. The predictive human data generated helps de-risk projects and add commercial value through early indications of drug safety, efficacy and absorption characteristics, informing early proof-of-concept.

Accredited as a Research Tissue Bank, the company has established an extensive network of tissue collaborators, in both the UK and USA.

Dr David Bunton, CEO, REPROCELL Europe, said: “We are excited to be working closely with the Medicines Discovery Catapult and to be part of a select group of companies developing innovative approaches to drug discovery. We hope that our combined services will accelerate drug development to the benefit of many UK biotechs.”

Dr Karen Bingham, COO, added: “Ethically-sourced human tissue samples are such an important resource for the prediction of efficacy and safety of novel drug compounds and are becoming increasingly important in the area of precision medicine. It's crucial that the NHS, industry and academia work together through collaborations such as Medicines Discovery Catapult in order to maximise use of this precious resource.”

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment




Digital Edition

Lab Asia December 2019

December 2019

In This Edition Mass Spectrometry & Spectroscopy - Translating Proteomic MALDi Tissue Typing to Clinical Pathology - Fusion Protein Complexes Analysed by CG-MALS - Non-equivalent, Multivalen...

View all digital editions

Events

SLAS 2020

Jan 25 2020 San Diego, CA, USA

Arab Health

Jan 27 2020 Dubai, UAE

Nano Tech 2020

Jan 29 2020 Tokyo, Japan

MEDLAB MIDDLE EAST

Feb 03 2020 Dubai, UAE

Smart Factory Expo (SFE 2020)

Feb 12 2020 Tokyo, Japan

View all events